Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adaptive, adjudicated, adjudication, advantage, affirmative, aged, agent, antidiabetic, auditor, back, backup, BioPharma, blinded, bone, break, broadening, bulk, calender, Catalent, Century, cGCP, cGLP, CGM, cGMP, charitable, cholangiocarcinoma, chosen, clarify, clarifying, commonly, constrained, constraint, CTS, dataset, debilitating, declare, declared, department, Deutschland, device, diagnostic, disproportionate, dissemination, distraction, diversified, dotatate, downgrade, EEA, EMA, emerging, expressly, fact, finite, footprint, forecasted, freight, GAAP, gastroenteropancreatic, Germany, glimepiride, GmbH, growing, Iceland, inaccurate, incentivize, indirect, inside, invoiced, Journal, justify, Kingdom, language, liberalize, Liechtenstein, lien, LP, Lu, lutetium, mandated, matter, membership, Mitigation, modification, neuroendocrine, Norway, older, owed, panel, parallel, PCAOB, plausible, PLC, pooled, prepay, prepayment, prompt, qualification, question, qui, radiopharmaceutical, rare, referenced, remeasure, remeasured, revised, RMS, routine, sector, shelf, shown, sNDA, SPs, stable, standing, stipulated, subordinated, sulfonylurea, tam, tranche, translate, transparency, unsuccessful, volume
Removed:
abdominal, administrator, affiliate, Affordability, apportioned, Artal, assist, biomarker, brand, branded, buy, cancer, carcinogenicity, CMC, coincide, companion, constitute, counsel, decided, deducting, delist, delisting, estate, exempt, float, flushing, fragmented, frequency, grace, guarantor, incurring, interaction, largest, lesser, listing, long, metabolite, minimum, movement, negotiated, nondeductible, notified, obligated, obligating, outpatient, overallotment, parity, partner, phantom, pill, placement, poison, preemptive, priced, pro, publicly, rata, restriction, retirement, seeking, surrendered, underwriting
Filing tables
Filing exhibits
- 10-K Annual report
- 10.11 Officer Stock Option Agreement
- 10.12 Officer Restricted Stock Unit Agreement
- 10.13 Stock Option Notice to Directors
- 10.26 Loan and Security Agreement
- 23.1 Consent of Ernst & Young LLP
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Principal Financial Officer
- 32.1 Certification of Principal Executive and Principal Financial Officers
- Download Excel data file
- View Excel data file
Related press release
Associated LXRX transcripts
LXRX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statements (Form S-8 Nos. 333-41532, 333-168678, 333-183020, 333-210145 and 333-217873) pertaining to the 2017 Equity Incentive Plan and to the 2017 Non-Employee Directors' Equity Incentive Plan of Lexicon Pharmaceuticals, Inc., and |
(2) | Registration Statements (Form S-3 Nos. 333-216825 and 333-220492) of Lexicon Pharmaceuticals, Inc. |
of our reports dated March 1, 2018, with respect to the consolidated financial statements of Lexicon Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Lexicon Pharmaceuticals, Inc., included in this annual report (Form 10-K) of Lexicon Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Houston, Texas
March 1, 2018